October 22nd 2024
The codes will go into effect on January 1, 2026.
Oral chemotherapy shows initial promise in treatment-resistant prostate cancer
July 14th 2023"The beauty is, now we can deliver a cisplatin-based chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy," says Shanta Dhar, PhD.
Inflation Reduction Act may lower patients' Medicare costs for prostate cancer treatment
July 13th 2023"Within the Inflation Reduction Act, there is a provision that will cap the out-of-pocket contribution for Medicare beneficiaries, dropping to $3250 in 2024, as well as $2,000 in 2025," says Brian Cortese.
PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future
July 11th 2023The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.
Analysis further links prostate cancer drug class with cognitive and functional toxicity
July 5th 2023“To our knowledge, these results are the first to suggest an association between second-generation [antiandrogens] and cognitive and functional toxic effects based on data from prospective [randomized controlled trials],” the investigators wrote.
Dr. Conor Driscoll on the effect of TNF alpha inhibitor use on prostate cancer risk
July 4th 2023"I would say that the take-home message of the study is that these immunosuppressive medications have alterations in the microbiology in a lot of these organs and a lot of these tumors," says Conor Driscoll, MD.
Long-term TNF alpha inhibitor use linked with decreased risk of prostate cancer
June 30th 2023"Prostate cancer showed a decreased risk, which we thought was very interesting, because it was the only cancer for which that signal existed, that there is possibly a protective effect of these medications," says Conor Driscoll, MD.
Evolving Practice Standards: Perirectal Spacing for Prostate Cancer
June 30th 2023In the first installment of this series, Juan Montoya, MD, discusses the results of the phase 3 pivotal trial of a polyethylene glycol-based hydrogel spacer, reviews real-world data on this product, and provides insights on the evolving practice standards for perirectal spacing in prostate cancer.
Diagnostics company opens new facility to scale up production of IsoPSA test for prostate cancer
June 29th 2023The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.
Dr. Basralian discusses the benefits of focal therapy in prostate cancer
June 29th 2023"Catheters go in, [and] they come out within 2 to 3 days for my patients. Therefore, the perioperative period is very easy for patients, whereas radical surgery requires catheters for 7 to 10 days," says Kevin R. Basralian, MD.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.